DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that...


DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that growing visibility on the company's Gen4 approval process should push the stock near, or possibly through its $12 price target over the next 12 months.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs